Skip to main content

Table 1 Current clinical trials used CHOP as backbone

From: Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma

Title NCT Number Conditions Status Interventions
Lenalidomide in combination with CHOP in patients with untreated PTCL NCT04423926 PTCL, NOS
AITL
ALK ALCL
Phase III–IV ALK+ ALCL
EATL
Recruiting
Phase 1/Phase 2
Drug: Lenalidomide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
Treatment of newly diagnosed peripheral T-cell lymphoma NCT03631862 Newly diagnosed peripheral T-cell lymphoma Recruiting
Phase 4
Drug: Apatinib
Drug: CHOP Regimen
Efficacy and safety of decitabine plus CHOP vs CHOP in patients with untreated peripheral T-cell lymphoma NCT03553537 Peripheral T-cell lymphoma Not yet recruiting
Phase 3
Drug: Decitabine
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
CC486-CHOP in patients with previously untreated peripheral T-cell lymphoma NCT03542266 Previously untreated peripheral T-cell lymphoma Active, not recruiting
Phase 2
Drug: CC-486 Administration
Drug: CHOP Administration
Chidamide with CHOP regimen for de Novo PTCL patients (CHOP: cyclophosphamide, etoposide, vincristine and prednisone; PTCL: Peripheral T cell lymphoma) NCT03268889 Peripheral T-cell lymphoma Recruiting
Not applicable
Drug: Chidamide
Clinical trial of chidamide combined with CHOP in peripheral T-cell lymphoma patients NCT02809573 Peripheral T-cell lymphoma Completed
Phase 1
Drug: Chidamide
Drug: cyclophosphamide
Drug: adriacin
Drug: vincristine
Drug: prednisone
A Dose-Finding Study of Folotyn® (pralatrexate injection) Plus CHOP With peripheral T-cell lymphoma (PTCL) NCT02594267 Peripheral T-cell lymphoma Active, not recruiting
Phase 1
Drug: Pralatrexate Injection
Compare efficacy of CHOP versus fractionated ICED in transplant-eligible patients with previously untreated PTCL NCT02445404 Peripheral T-cell lymphoma Recruiting
Phase 2
Drug: CHOP
Drug: fractionated ICED
Phase 1 dose finding study of belinostat for treatment of patients with peripheral T-cell lymphoma (PTCL) NCT01839097 Peripheral T-cell lymphoma Completed
Phase 1
Drug: Belinostat
Drug: CHOP
Efficacy and safety of romidepsin CHOP vs CHOP in patients with untreated peripheral T-cell lymphoma NCT01796002 Peripheral T-cell lymphoma Active, not recruiting
Phase 3
Drug: Romidepsin + CHOP
Drug: CHOP
ECHELON-2: a comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30-positive mature T-cell lymphomas NCT01777152 Anaplastic large-cell lymphoma
Non-Hodgkin lymphoma
T-cell lymphoma
Active, not recruiting
Phase 3
Drug: brentuximab vedotin
Drug: CHOP/CHP
CHOP vs GEM-P in 1st line treatment of T-cell lymphoma, multicentre phase II study NCT01719835 Peripheral T-cell lymphoma NOS
Anaplastic large cell lymphoma, ALK-negative
Angioimmunoblastic T-cell lymphoma
Hepatosplenic Gamma/Delta T-cell lymphoma
Enteropathy-associated T-cell lymphoma
Active, not recruiting
Phase 2
Drug: Cyclophosphamide
Drug: Gemcitabine
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
Drug: methylprednisolone
Drug: Cisplatin
Intensive chemo-immunotherapy as first line treatment in adult patients with peripheral T-cell lymphoma NCT01679860 Lymphoma, T-cell, peripheral Completed
Phase 2
Procedure: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT
Drug: Clin B (CHOP-CAMPATH) Chemo-immunotherapy
Treatment of peripheral T-cell lymphoma NCT01664975 Peripheral T-cell lymphoma Completed
Phase 4
Drug: GDPT regimen
Drug: CHOP regimen
Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients NCT01420679 Peripheral T-cell lymphoma Terminated
Phase 3
Drug: Pralatrexate injection
A phase 3 trial of E7777 in combination with CHOP compared with CHOP alone for the first-line treatment of peripheral T-cell lymphoma NCT01355783 Peripheral T-cell lymphoma Withdrawn
Phase 3
Drug: E7777
A study of escalating doses of romidepsin in association with CHOP in the treatment of peripheral T-cell lymphomas NCT01280526 Peripheral T-cell lymphoma Completed
Phase 1/Phase 2
Drug: Romidepsin and CHOP
RAD001 combined with CHOP in newly diagnosed peripheral T-cell lymphomas NCT01198665 Peripheral T-cell lymphoma unspecified
Anaplastic large cell lymphoma, ALK-negative
Angioimmunoblastic T cell lymphoma
Cutaneous T cell lymphoma
Completed
Phase 1/Phase 2
Drug: RAD001 (Everolimus)
Safety study of darinaparsin in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to treat lymphoma NCT01139359 Lymphoma Withdrawn
Phase 1
Drug: darinaparsin
Drug: CHOP
Endostar combined with CHOP regimen as first line chemotherapy for peripheral T cell lymphoma NCT00974324 T cell lymphoma Unknown
Phase 2
Drug: endostar and CHOP
The effectiveness of alemtuzumab given in combination with CHOP and ESHAP in patients newly diagnosed with peripheral T-cell lymphoma (PTCL) NCT00930605 Peripheral T-cell lymphoma Completed
Phase 2
Drug: CHOP regimen alternate with ESHAP regimen
Drug: Alemtuzumab
CD4 in combination with CHOP in treating non-cutaneous peripheral T cell lymphoma NCT00893516 T-cell Lymphoma Terminated
Phase 2
Biological: CHOP + CD4
Drug: CHOP
SAHA + CHOP in untreated T-cell non-Hodgkin's lymphoma NCT00787527 Lymphoma Completed
Phase 1/Phase 2
Drug: Zolinza (vorinostat)
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Immunotherapy in peripheral T cell lymphoma—the role of alemtuzumab in addition to dose dense CHOP NCT00725231 Peripheral T cell lymphoma, unspecified
Angioimmunoblastic lymphadenopathy
Extranodal NK/T-cell Lymphoma
Unknown
Phase 3
Biological: alemtuzumab
Drug: chemotherapy
Alemtuzumab and CHOP in T-cell lymphoma NCT00646854 Lymphoma, T-cell, peripheral Completed
Phase 3
Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab
Drug: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
Alemtuzumab and CHOP chemotherapy for aggressive histological peripheral T-cell lymphomas NCT00453427 Peripheral T-cell lymphomas Completed
Phase 1/Phase 2
Drug: Alemtuzumab (Campath-1H)
The effectiveness of alemtuzumab combination with CHOP to treat patients newly diagnosed with PTCL NCT00441025 Peripheral T-cell lymphoma Terminated
Phase 2
Drug: Alemtuzumab
Bortezomib and CHOP in patients with advanced stage aggressive T cell or natural killer (NK)/T cell lymphomas NCT00374699 Peripheral T-cell lymphomas
Non-hodgkin lymphoma
Completed
Phase 1/Phase 2
Drug: Velcade
A pilot study to determine the safety of the combination of Ontak in combination with CHOP in peripheral T-cell lymphoma NCT00337987 Peripheral T-cell lymphoma Completed
Phase 2
Drug: Ontak
Drug: CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
A study of ONTAK and CHOP in newly diagnosed, peripheral T-cell lymphoma NCT00211185 Lymphoma, T-cell, peripheral Completed
Phase 2
Drug: Denileukin diftitox
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Other: Pegfilgrastim
  1. The detail show on https://clinicaltrials.gov/